CTOs on the Move

American Board of Nuclear Medicine

www.abnm.org

 
American Board of Nuclear Medicine is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.abnm.org
  • 4555 Forest Park Ave
    Saint Louis, MO USA 63108
  • Phone: 314.367.2225

Executives

Name Title Contact Details

Similar Companies

Nashai

Nashai is a Nashville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Thermo Fisher Scientific

Thermo Fisher Scientific is an American supplier of scientific instrumentation, reagents and consumables, and software services.

Flo Health

Flo Health is a developer of Flo, the fastest growing AI-driven women`s health product that encompasses solutions for girls and women at every stage of their life (start of menstruation, cycle tracking, preparation for conception, pregnancy, early motherhood, menopause).

Civetta Therapeutics

Civetta Therapeutics was founded by William Sellers (Broad Institute and Dana-Farber Cancer Institute) and Eric Fischer (Dana Farber Cancer Institute and Harvard Medical School) to advance new medicines through small molecule intervention targeting propeller domains with the goal of developing important therapeutics for cancer and other indications.

Regado Biosciences

Regado Biosciences, Inc., is a biopharmaceutical company focused on the discovery and development of novel, oligonucleotide-based actively controllable therapeutics. Our initial focus is on applications in the acute and sub-acute cardiovascular therapeutic area. The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen. REG1 is currently being evaluated in the REGULATE-PCI trial, a worldwide Phase 3 trial enrolling 13,200 patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI), a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. Regado's actively controllable product candidates have the potential to improve patient outcomes and enhance the patient experience, provide direct therapeutic control to physicians and reduce overall treatment costs.